Midive (Riociguat)

Riociguat, the active ingredient in Midive, is a soluble guanylate cyclase stimulator presented as an oral tablet for oral use. It is indicated for the treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension in adult patients. The medication is formulated for systemic absorption and is part of the therapeutic options for patients with elevated pulmonary vascular resistance.

GNH USA supplies Midive as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with a focus on quality assurance, regulatory compliance and reliable logistics across multiple continents.

Midive (riociguat) is used in the management of diseases affecting the pulmonary vasculature.

Pulmonary arterial hypertension: improves exercise capacity and delays disease progression. Chronic thromboembolic pulmonary hypertension: enhances hemodynamic parameters and functional class. Inoperable chronic thromboembolic pulmonary hypertension: provides a medical option when surgical intervention is not feasible.

Riociguat may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Headache - Dizziness - Nausea - Diarrhea - Dyspepsia - Mild hypotension

Serious or Rare Side Effects: - Severe hypotension or syncope - Pulmonary hemorrhage or hemoptysis - Liver enzyme elevation - Anemia or other hematologic abnormalities - Pulmonary edema

Before initiating therapy, clinicians should evaluate patient-specific risk factors and monitor for potential complications. - Blood pressure monitoring: check baseline and regularly during treatment. - Concomitant nitrates: avoid due to additive hypotensive effect. - Hepatic function: assess liver enzymes before and during therapy. - Renal impairment: adjust use in severe renal dysfunction. - Pregnancy: safety not established; avoid use in pregnant women. - Store at room temperature: keep in the original packaging, protect from moisture and direct sunlight.

Riociguat can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Nitrates (e.g., nitroglycerin): risk of profound hypotension. - Phosphodiesterase‑5 inhibitors (e.g., sildenafil): additive vasodilatory effect. - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase riociguat exposure.

Moderate Interactions (Monitor Closely): - Antihypertensive agents: may enhance blood‑pressure lowering. - Anticoagulants/antiplatelets: monitor for bleeding. - Diuretics: watch for electrolyte disturbances and volume depletion.